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Introduction
H
epatitis  B  is  one  of  the  most  common 
infectious diseases, with about 350 million 
infected  people  worldwide,  predominantly  (75% 
to 80%) in Asia and Eastern Europe (1). About 1 
million deaths annually are estimated to be caused 
by hepatitis B infection, which has been the main 
risk factor for cirrhosis and hepatocellular carcinoma 
worldwide (2). More than 3% of Iranians has been 
reported to be hepatitis B virus (HBV) positive (3, 4). 
Hepatitis Delta virus (HDV), is a defective ssRNA 
virus, in which HBV surface proteins are needed for 
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Backgrounds and Aims: Hepatitis Delta Virus (HDV) is a defective ssRNA virus requiring the provision of hepatitis B virus 
(HBV) for packaging of new HDV virions. Since the epidemiological features of HDV in this part of Iran seem to be unknown, 
the aim of this research was to determine the seroprevalence of HDV of hepatitis B surface antigen positive (HBsAg+) 
in blood donors, injecting drug users, hemophiliacs, hemodialysis and thalassemic patients in the city of Tabriz in north-
western Iran. 
Methods: The numbers of patients who were screened in the years 2006-2007 were 100 hemodialysis patients, 165 
blood donors and 90 intravenous drug users, or a total of 355 patients who were HBsAg+ and randomly selected at the 
Tabriz Regional Educational Blood Center. Anti-HDV antibodies (IgM), alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels in serum samples were measured. 
Results: Eight of the hemodialysis patients (8%), 3 of the 165 blood donors (1.8%) and 9 intravenous drug addicts 
(10%) were HDV-IgM antibody-positive. Out of 152 serum samples collected in the hemophiliac population, only 11 
samples were HBsAg+ (7.23%), and anti-HDV IgM antibodies were detected in just 2 cases. Also out of 112 thalassemic 
patients’ sera specimens, only 2 samples was HBsAg+, and HDV-IgM antibodies were negative. The seropositivity of anti-
HDV antibodies was 6.01%. The study of serum ALT levels in HBV-positive and HDV-positive patients showed obvious 
elevation in more than 95% of cases. 
Conclusions: The results show the endemicity of HDV infection in Tabriz. HDV infection in Iran could be controlled by 
nationwide HBV vaccination.
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packaging of new HDV virions: it is usually studied 
in  hepatitis  B  surface  antigen-positive  (HBsAg+) 
patients (5-8). Acute and chronic liver diseases have 
been reported in patients infected with HDV. It is 
estimated  that  more  than  15  million  patients  are 
infected with HDV. The incidence of HDV infection 
in the western regions of Asia, Eastern Europe and 
Italy is high in comparison with the rest of the world 
(9-11). HDV has been reported to be endemic in the 
Middle East (12). A considerable body of evidence 
now suggests that simultaneous infection with HDV 
leads to an acceleration of the progress of chronic 
HBV infection into chronic hepatitis, cirrhosis and 
finally, hepatocellular carcinoma (13). It has also been 
reported  that  co-infection  or  super-infection  with 
HDV may occur in 25% of chronic HBV carriers. 
Only 15% of infected patients with HBV develop 
cirrhosis  in  comparison  to  70%–80%  of  HDV-
infected patients who develop cirrhosis (14). 
Since  the  epidemiological  features  of  HDV  in 
northwestern  Iran  seem  to  be  unknown,  the  aim 
of this research was to manage the epidemiological 
features of HDV infection in high-risk populations 
in the city of Tabriz, the capital of the province of 
Western  Azarbaijan,  one  of  the  30  provinces  of 
Iran. This study was in line with the objective of 
investigating the risk of HDV transmission in at-risk 
populations in the category of HBsAg+, including 
blood  donors,  injecting  drug  users,  hemophiliacs, 
hemodialysis and thalassemic patients in this part of 
Iran. The reason for using anti-HDV IgM antibodies 
to make a diagnosis of HDV infection was to ensure 
that patients had been newly-infected, and the results 
were  due  to  recent,  and  not  long-term  infection. 
This will facilitate the management of the disease in 
Tabriz, and the detailed evaluation of the distribution 
and characteristics of HDV in this part of Iran. 
Materials and Methods
Five  different  groups  of  subjects,  including 
hemodialysis  patients,  blood  donors,  intravenous 
drug  users,  hemophiliac  and  thalassemic  patients 
were studied. The tests were performed as part of a 
routine clinical assessment. Out of the 619 patients 
who were studied in this research, 100 patients were 
hemodialysis patients, 165 were blood donors and 
90 were intravenous drug users. In total, 355 patients 
who were HBsAg+, were randomly selected at the 
Regional  and  Educational  Division  of  the  Blood 
Transfusion  Organization  Research  Center.  Their 
serum samples were screened for immunoglobulin 
M  antibodies  to  hepatitis  delta  virus  (anti-HDV 
IgM),  using  Diapro  kits  and  the  enzyme-linked 
immunosorbent assay (ELISA) method. Out of 152 
hemophiliac and 112 thalassemic patients, only 11 
and 2 samples, respectively, were HBsAg+. ALT and 
AST levels in serum samples were measured by the 
IFCC method using Pars Azmoon kits. The Fisher 
exact and chi-square tests were performed to analyze 
the data obtained by using SPSS, version 13.
Results
Among  the  619  patients  screened  in  the  years 
2006-2007. 100 hemodialysis patients, 165 blood 
donors  and  90  intravenous  drug  users,  who  were 
HBsAg+, were screened for anti-HDV IgM. Eight of 
the hemodialysis patients (8%), 3 of the 165 blood 
donors (1.8%) and 9 of the intravenous drug users 
(10%) were anti-HDV IgM positive. Out of 152 
serum samples collected from hemophiliac patients, 
only 11 samples were HBsAg+ (7.23%), and anti-
HDV IgM antibodies were detected in just 2 (0.18 
%) cases in the HBsAg+ patients. Also, out of 112 
sera from thalassemics, only 2 samples were HBsAg+, 
and anti-HDV IgM antibodies were negative in all of 
the patients (Table 1). A study of serum ALT levels in 
HBV+ and HDV+ patients showed obvious elevation 
(100%) in all of them (Table 2). 
Discussion
The  present  study  is,  to  the  best  of  our 
knowledge, one of the few published papers which 
has organized the epidemiological data about the co-
infection of HDV among HBsAg+ simultaneously 
into the categories of blood donors, injecting drug 
users,  hemophiliacs,  hemodialysis  and  thalassemic 
patients  in Tabriz’s  population.  We  conducted  an 
epidemiological  study  of  619  patients,  and  based 
on the data obtained, we have understood that the 
seropositivity of anti-HDV antibodies was 6.01%, 
showing  the  endemicity  of  HDV  infection  in 
Tabriz, consistent with the results (6%) that have 
been previously reported among HBsAg+ subjects 
from Tabriz (15). This shows that the seroprevalence 
of HDV antibodies has been almost constant over 
a period of about 5 years, in this part of Iran. This 
is in contrast with another report from Golestan, 
a  northeastern  province  in  Iran,  which  shows  an 
increasing  rate  of  HDV  infection  during  the  last 
decade  (16). The  results  obtained  in  this  research 
were significantly higher than in the reports in some 
previous Iranian research  (17, 18). HDV antibodies 
were reported in 2.5% of the asymptomatic HBsAg+ 
population (17). In a similar study from Hamadan, a Hepatitis Monthly, Spring 2010; 10(2): 110-115
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western province of Iran, a similar prevalence (2.4%) 
of  HDV  infection  was  reported  (18).  Hassanjani-
Roshan  and  Taheri,  in  2000,  reported  an  HDV 
seroprevalence of 2% in HBsAg+ carriers in Babol, 
another city in northern Iran (4), which is a finding 
consistent with previous reports from Iran. Another 
report  indicates  a  HDV  seroprevalence  of  5.7% 
in  Iran,  among  HBV-infected  patients  (19).  The 
prevalence of HDV infection among the HBsAg+ 
population has been reported to be 24.4%, 16.6%, 
4%,  2.2%,  1.6%,  and  1.5%,  in  Bangladesh  (20), 
Pakistan  (21), Mexico  (22), Taiwan  (23), Spain  (24), 
and Yugoslavia (25), respectively. 
From Table 1, it can be concluded that in terms 
of patients’ place of residence, whether in rural or in 
urban areas, the majority of the population under 
study were living in an urban area, in Tabriz, the 
capital  of  the  province  of  Western  Azarbaijan,  as 
opposed to a rural area. In terms of occupational status, 
63.62%, 56%, 67.76% and 81.11% of the patients 
were employed by non-governmental organizations 
(NGO) and were members of the following groups, 
respectively:  blood  donors,  hemodialysis  patients, 
hemophiliacs and injecting drug users. 
As can be seen in Table 3, 72.72%, 69%, 61.84%, 
77.77% and 53.57% of the patients under study were 
blood  donors,  hemodialysis  patients,  hemophiliac 
patients,  thalassemic  patient  and  injecting  drug 
users, respectively. Table 3 also shows that antibodies 
against HDV were positive in 22 patients, including 
20 males and 2 females. Consequently, this study 
shows that among infected patients, males (90%) were 
more often infected with HDV than were females 
(10%). This might be due to high-risk behavior in 
men, such as intravenous drug abuse. These results 
are  consistent  with  previous  reports  from  Babol, 
another city in northern Iran (4) and from Pakistan 
(21). One of the limitations that we faced in this 
study was the number of males and females under 
study, which was unequal, a factor which might have 
affected  the  results  obtained  in  this  research.  On 
the other hand, the data obtained in this study has 
suggested that gender may be connected with HDV 
infection. However, we did not find any significant 
relationship between HDV infection and residential 
area, occupation and marital factors. 
Based on the data shown in Table 4, it can be 
concluded that 3 of the blood donors (1.81%), 8 
of the patients undergoing hemodialysis (8%), and 
9 of the intravenous drug users (10%), had anti-
HDV IgM antibodies. Out of 152 serum samples 
collected from hemophiliacs, HDV-IgM antibodies 
were detected in just 2 cases, (1.3%) which is a lesser 
number than in reports from some other countries. 
Troisi et al., 1993 showed 9.1% of anti-HDV in the 
hemophiliac population of the United States. Also, in 
Table 1. Distribution of the blood donors, injecting drug users, hemophiliacs, 
hemodialysis and thalassemic patients studied in this research according 
to residential area, occupation, the level of literacy and marital status in 
Tabriz.
      Factors Under 
                 Study
Groups Under 
Study
Residential Area Occupation Marital status
Tabriz       County Govermental     NGO Single       Married
Blood Donors 58.78%     41.22% 36.36%            63.64% 38.79%      61.21%
Hemodialysis
Patients
72%          28% 44%                 56% 68%           32%
Hemophiliacs 55.26%     44.74% 32.24%            67.76% 25.66%      74.34%
Injecting Drug Users 83.33%     16.67% 18.89%            81.11% 30%           70%
Thalassemics 80.36%     19.64% -                     - 100%              -
Table 2. The comparison of level of liver enzymes (AST and ALT) in HDV+ and 
HDV- patients studied in this research.
Liver Enzymes 
Groups
 Under Study
ALT AST
(HDV+) (HDV-) (HDV+) (HDV-)
Blood Donors 
n=3
100%>normal
n=162
50%> normal
n=3
100%>normal
n=162
45%> normal
Hemodialysis
Patients 
n=8
100%>normal
n=92
60%> normal
n=8
100%>normal
n=92
60%> normal
Injecting Drug Users
n=9
100%>normal
n=81
60%> normal
n=9
100%>normal
n=81
65%> normal
Hemophiliacs 
n=2
100%>normal
n=9
60%> normal
n=2
100%>normal
n=9
60%> normal
Thalassemics 
-
normal
n=112
normal
-
normal
n=112
normalHepatitis Monthly, Spring 2010; 10(2): 110-115
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all 112 patients with thalassemia, antibodies against 
HDV-IgM were negative. 
A  research  study  in  India  showed  that  16.7% 
of  HBsAg+  multi-transfused  thalassemics  had 
antibodies  against  HDV  (26).  A  similar  study 
performed  on  thalassemic  children  in  Bangladesh 
showed no positive antibodies (27), the latter results 
being  consistent  with  our  current  findings.  From 
Table 4, it can also be concluded that the higher rates 
of  anti-HDV  IgM  antibodies  were  seen  in  single 
people living in Tabriz and among NGO personnel. 
This  would  indicate  the  possibility  of  risk-taking 
behaviors among these groups.
Table 2 shows an obvious elevation in the level of 
liver enzymes in the serum of all patients, including 
ALT and AST levels, in HBV+ and HDV+ patients. 
Huo et al., 2004 showed that 5% of injecting drug 
users studied in Taiwan had HDV antibodies (28). A 
study performed by Cross et al., 2008, on injecting 
drug  users  showed  that  28.1%  of  the  population 
under study in Eastern Europe, 26.8% in Africa and 
7.3% in the Middle East had antibodies against HDV 
(29). Chen et al., 1992 showed a 2.2% positive anti-
HDV in blood donors in Taiwan (23) in comparison 
to the rate in Indonesia (0.5%) (30). Torabi et al., 
2002, showed that 4.6% of HBsAg+ blood donors in 
Tabriz (15) had antibodies against HDV, whereas our 
study showed 1.81% anti-HDV in this population. 
This shows a declining rate of 2.59% in this group 
of people over a period of 5 years, which may show 
the effects of vaccination in this region of Iran. On 
the other hand, since injecting drug users were listed 
as  the  largest  group  of  HDV-infected  patients  in 
Tabriz, our research suggests that HDV screening 
is essential among injecting drug users. Continuous 
diagnostic laboratory testing may show the way to 
the most rational therapeutic strategy in overcoming 
the disease. 
Some  countries  have  organized  successful 
sanitation  projects  to  insure  the  decline  of  the 
prevalence of HDV infection (11, 31-33). Our results 
suggest that in Tabriz, HDV infection, as well, can 
be controlled. Since 2005, a national plan has been 
developed in Iran to vaccinate teenagers against HBV. 
Efforts to reduce HBV and consequently, HDV, in 
Tabriz and in other provinces can be implemented 
by means of broad-scale vaccination in the country. 
However,  essential  research  by  practitioners  and 
health-care  managers  alike  is  required  for  the 
evaluation of the effectiveness of HBV vaccination 
Table 3. Distribution of the blood donors, injecting drug users, 
hemophiliacs, hemodialysis and thalassemic patients studied in 
this research according to sex in Tabriz.
      Factors Under 
Study
Groups Under 
Study
Sex
No. of Positive HDV 
Antibody
Male Female Male Female
Blood donors 72.73% 27.27% 2 -
Hemodialysis Patients 69% 31% 7 1
Hemophiliacs 61.84% 38.16% 2 -
Injecting Drug Users 53.57% 46.43% 8 1
Thalassemics 80.36% 19.64% - -
P-value < 0.004 -
Table 4. Distribution of HDV positive patients studied in this search according to marital status, residential 
area and occupation in Tabriz.
Factors Under 
Study
Groups Under 
Study
Residential Area
The Whole No. (HDV+)
Occupation
The Whole No. (HDV+)
Marital Status
The Whole No. (HDV+)
Tabriz Count Governmental NGO Single Married
Blood Donors (165) 97(2) 68(1) 60(1) 105(2) 64(3) 101(-)
Hemodialysis Patients (100) 72(4) 28(4) 44(2) 56(6) 68(5) 32(3)
Hemophiliacs (152) 84(2) 68(-) 49(1) 103(1) 39(-) 113(2)
Injecting Drug Users (90) 75(8) 15(1) 17(1) 73(8) 27(5) 63(4)
Thalassemics (112) 90(-) 22(-) - - - -
P-value 0.1 0.8 0.6Hepatitis Monthly, Spring 2010; 10(2): 110-115
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programs  in  controlling  HBV,  and  consequently 
HDV. This effort could provide valuable information 
on the circulation of HDV. The Iranian authorities 
could  prioritize  government  programs  to  control 
HDV  infection  nationwide.  A  regulatory  HDV 
committee and subcommittees could be established 
as HIV committees and subcommittees have been, 
which have so far been known to be very effective. 
Also  in  each  province  of  Iran,  representatives  of 
blood  transfusion  organizations,  the  ministry  of 
education,  universities  of  medical  sciences,  and 
prison authorities need to perform further research 
to consider other methods of HDV transmission and 
to reduce the prevalence of HDV, as future goals. 
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